Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:
“At CIOT26 Dr. Ben Solomon discusses advanced ALK NSCLC and the standard that lorlatinib has set with the median PFS not yet reached after 7 years of follow up. Next gen agents like neladalkib showing promise – will it move earlier? Will degraders like TRI-611 overcome resistance?”
Other articles featuring Stephen V Liu on OncoDaily.
